Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV
- 4 February 2009
- Vol. 27 (12), 1848-1857
- https://doi.org/10.1016/j.vaccine.2009.01.041
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivorsNature, 2008
- Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infectionsVaccine, 2008
- Viral and Host Factors in Human Respiratory Syncytial Virus PathogenesisJournal of Virology, 2008
- Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and BVaccine, 2007
- Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatmentVirus Research, 2006
- Human Parainfluenza Type 4 Infections, CanadaEmerging Infectious Diseases, 2006
- Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSVJournal of Virology, 2004
- Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infantsThe Pediatric Infectious Disease Journal, 1996
- An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccinesVirus Research, 1994
- The development of antibodies against Sendai virus in childhoodArchiv für die gesamte Virusforschung, 1967